Albert Ong

10.5k total citations · 1 hit paper
142 papers, 5.6k citations indexed

About

Albert Ong is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Albert Ong has authored 142 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Genetics, 70 papers in Molecular Biology and 38 papers in Pathology and Forensic Medicine. Recurrent topics in Albert Ong's work include Genetic and Kidney Cyst Diseases (102 papers), Renal and related cancers (53 papers) and Biomedical Research and Pathophysiology (36 papers). Albert Ong is often cited by papers focused on Genetic and Kidney Cyst Diseases (102 papers), Renal and related cancers (53 papers) and Biomedical Research and Pathophysiology (36 papers). Albert Ong collaborates with scholars based in United Kingdom, United States and Netherlands. Albert Ong's co-authors include Peter C. Harris, Andrew J. Streets, Leon G. Fine, Ming‐Yang Chang, Christopher J. Ward, Yaoxian Xu, D. A. Allwood, Shaowei Zhang, Liangxu Lin and I M Ross and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Albert Ong

142 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chronic kidney disease and the global public health agenda: an international consensus

2024 387 citations Albert Ong et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Albert Ong United Kingdom	41	3.3k	2.9k	1.1k	978	541	142	5.6k
W. Charles O’Neill United States	48	1.3k 0.4×	1.7k 0.6×	488 0.4×	2.3k 2.3×	1.2k 2.3×	115	5.8k
Martine Cohen‐Solal France	40	755 0.2×	2.4k 0.8×	403 0.4×	813 0.8×	269 0.5×	242	6.1k
Francesco Emma Italy	41	666 0.2×	2.4k 0.8×	1.5k 1.4×	2.7k 2.8×	812 1.5×	184	6.3k
Bruce G. Robinson Australia	56	1.6k 0.5×	3.4k 1.1×	790 0.7×	906 0.9×	1.3k 2.4×	227	11.3k
Elena Levtchenko Belgium	41	657 0.2×	1.9k 0.6×	2.2k 1.9×	1.6k 1.7×	932 1.7×	257	6.4k
Willy Lissens Belgium	43	1.8k 0.5×	3.3k 1.1×	310 0.3×	142 0.1×	926 1.7×	235	7.0k
Agnès Linglart France	41	2.4k 0.7×	2.1k 0.7×	636 0.6×	2.0k 2.0×	443 0.8×	243	6.0k
Jill T. Norman United Kingdom	34	546 0.2×	1.6k 0.5×	274 0.2×	1.1k 1.1×	717 1.3×	64	3.8k
Rachel Lennon United Kingdom	32	459 0.1×	1.5k 0.5×	338 0.3×	1.9k 1.9×	408 0.8×	99	3.7k
Alexander G. Bick United States	35	966 0.3×	1.3k 0.4×	262 0.2×	202 0.2×	150 0.3×	106	5.0k

Countries citing papers authored by Albert Ong

Since Specialization

Citations

This map shows the geographic impact of Albert Ong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Ong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Ong more than expected).

Fields of papers citing papers by Albert Ong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Ong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Ong. The network helps show where Albert Ong may publish in the future.

Co-authorship network of co-authors of Albert Ong

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Ong. A scholar is included among the top collaborators of Albert Ong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Ong. Albert Ong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harris, Tess, Neal Padmanabhan, Roslyn Simms, et al.. (2025). Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update. BMC Nephrology. 26(1). 79–79. 2 indexed citations

Gall, Émilie Cornec-Le & Albert Ong. (2025). Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025. Clinical Kidney Journal. 18(Supplement_2). ii17–ii25. 1 indexed citations

Durkie, Miranda, Christopher M. Watson, Peter R. Winship, et al.. (2023). The Common PKD1 p.(Ile3167Phe) Variant Is Hypomorphic and Associated with Very Early Onset, Biallelic Polycystic Kidney Disease. Human Mutation. 2023. 1–8. 2 indexed citations

Gansevoort, Ronald T., Ali Hariri, Pascal Minini, et al.. (2022). Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. American Journal of Kidney Diseases. 81(5). 517–527.e1. 12 indexed citations

Perrone, Ronald D., Ali Hariri, Pascal Minini, et al.. (2022). The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD. Kidney Medicine. 4(10). 100538–100538. 7 indexed citations

Durkie, Miranda, et al.. (2020). Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease. Genetics in Medicine. 23(4). 689–697. 40 indexed citations

Mills, Mark T, et al.. (2020). Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open. 10(1). e032620–e032620. 33 indexed citations

Hopp, Katharina, Émilie Cornec-Le Gall, Sarah R. Senum, et al.. (2019). Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International. 97(2). 370–382. 49 indexed citations

Harris, Tess, Richard Sandford, Olivier Devuyst, et al.. (2017). European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. Nephrology Dialysis Transplantation. 33(4). 563–573. 26 indexed citations

10.

Fragiadaki, Maria, Madeleine Themanns, Barbara Maurer, et al.. (2017). STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Kidney International. 91(3). 575–586. 40 indexed citations

11.

Ong, Albert, Olivier Devuyst, Bertrand Knebelmann, & Gerd Walz. (2015). Autosomal dominant polycystic kidney disease: the changing face of clinical management. The Lancet. 385(9981). 1993–2002. 192 indexed citations

12.

Yang, Bo, Sixiu Chen, Guang Yang, et al.. (2015). New onset diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease: systematic review protocol. BMJ Open. 5(11). e008440–e008440. 3 indexed citations

13.

Liu, Yang, Andres Käch, Urs Ziegler, et al.. (2013). The Role of Phospholipase D in Modulating the MTOR Signaling Pathway in Polycystic Kidney Disease. PLoS ONE. 8(8). e73173–e73173. 18 indexed citations

14.

Chang, Ming‐Yang & Albert Ong. (2011). Endothelin in Polycystic Kidney Disease. Contributions to nephrology. 172. 200–209. 12 indexed citations

15.

Mao, Zhiguo & Albert Ong. (2009). Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present Fears. Nephron Clinical Practice. 112(4). c230–c241. 20 indexed citations

16.

Parker, Ernest T., Linda J. Newby, Claire C. Sharpe, et al.. (2007). Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney International. 72(2). 157–165. 71 indexed citations

17.

Hamer, Rizwan, et al.. (2007). Polycystic Kidney Disease Is a Risk Factor for New-Onset Diabetes After Transplantation. Transplantation. 83(1). 36–40. 84 indexed citations

18.

Huls, Gerwin, Marc van de Wetering, Mahmoud Loghman‐Adham, et al.. (2004). Aberrant Polycystin-1 Expression Results in Modification of Activator Protein-1 Activity, whereas Wnt Signaling Remains Unaffected. Journal of Biological Chemistry. 279(26). 27472–27481. 35 indexed citations

19.

Ong, Albert & Leon G. Fine. (1994). Tubular-Derived Growth Factors and Cytokines in the Pathogenesis of Tubulointerstitial Fibrosis: Implications for Human Renal Disease Progression. American Journal of Kidney Diseases. 23(2). 205–209. 80 indexed citations

20.

Wallace, Mark N., et al.. (1968). Persistent alkalosis and hypo kalemia caused by surreptitious vomiting human enz renin angiotensin cardio vasc. QJM. 38(148). 577–588. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact